Skip to main content
Journal cover image

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.

Publication ,  Journal Article
Fong, Y; Dang, L; Zhang, B; Fintzi, J; Chen, S; Wang, J; Rouphael, NG; Branche, AR; Diemert, DJ; Falsey, AR; Losada, C; Baden, LR; Frey, SE ...
Published in: Clin Infect Dis
February 5, 2025

For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.

Duke Scholars

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 5, 2025

Volume

80

Issue

1

Start / End Page

223 / 227

Location

United States

Related Subject Headings

  • Vaccines, Synthetic
  • SARS-CoV-2
  • Middle Aged
  • Microbiology
  • Male
  • Immunization, Secondary
  • Humans
  • Female
  • COVID-19 Vaccines
  • COVID-19
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fong, Y., Dang, L., Zhang, B., Fintzi, J., Chen, S., Wang, J., … Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. (2025). Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis, 80(1), 223–227. https://doi.org/10.1093/cid/ciae465
Fong, Youyi, Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen, Jing Wang, Nadine G. Rouphael, et al. “Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.Clin Infect Dis 80, no. 1 (February 5, 2025): 223–27. https://doi.org/10.1093/cid/ciae465.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 Feb 5;80(1):223–7.
Fong, Youyi, et al. “Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.Clin Infect Dis, vol. 80, no. 1, Feb. 2025, pp. 223–27. Pubmed, doi:10.1093/cid/ciae465.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Yu C, Magaret CA, Molitor C, Borate B, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Roberts PC, Follmann D, Gilbert PB, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 Feb 5;80(1):223–227.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 5, 2025

Volume

80

Issue

1

Start / End Page

223 / 227

Location

United States

Related Subject Headings

  • Vaccines, Synthetic
  • SARS-CoV-2
  • Middle Aged
  • Microbiology
  • Male
  • Immunization, Secondary
  • Humans
  • Female
  • COVID-19 Vaccines
  • COVID-19